1. Arastehfar A, Khodavaisy S, Daneshnia F, Najafzadeh MJ, Mahmoudi S, Charsizadeh A, et al. Molecular identification, genotypic diversity, antifungal susceptibility, and clinical outcomes of infections caused by clinically underrated yeasts, Candida orthopsilosis, and Candida metapsilosis: an Iranian multicenter study (2014–2019). Front Cell Infect Microbiol 2019; 9:264-75. doi: 10.3389/fcimb.2019.00264.

2. Hedayati MT, Armaki MT, Charati JY, Hedayati N, Seyedmousavi S, Denning DW. Burden of fungal infections in Iran. J Infect Dev Ctries 2018;12:910-18. doi: 10.3855/jidc.10476.

3. Mahdavi Omran S, Rezaei Dastjerdi M, Zuashkiani M, Moqarabzadeh V, Taghizadeh-Armaki M. In vitro antifungal susceptibility of Candida species isolated from Iranian patients with denture stomatitis. Biomed Res Int 2018; 2018:3086586. doi: 10.1155/2018/3086586.

4. Fazeli A, Kordbacheh P, Nazari A, Ghazvini RD, Mirhendi H, Safara M, et al. Candiduria in hospitalized patients and identification of isolated Candida species by morphological and molecular methods in Ilam, Iran. Iran J Public Health 2019;48:156-61.

5. Aghili S R , Abastabar M , Soleimani A , Haghani I , Azizi S. High prevalence of asymptomatic nosocomial candiduria due to Candida glabrata among hospitalized patients with heart failure: a matter of some concern? Curr Med Mycol 2020;6:1-8.doi: 10.18502/cmm.6.4.5327.

6. Sinh CT, Loi CB, Minh NTN, Lam NN, Quang DX, Quyet D, et al. Species Distribution and Antifungal Susceptibility Pattern of Candida Recovered from Intensive Care Unit Patients, Vietnam National Hospital of Burn (2017–2019). Mycopathologia 2021;186: 543-51.doi: 10.1007/s11046-021-00569-7.

7. Khadka S, Sherchand JB, Pokhrel BM, Parajuli K, Mishra SK, Sharma S, et al. Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal. BMC Res Notes 2017;10:1-5. doi: 10.1186/s13104-017-2547-3.

8. Khan M, Ahmed J, Gul A, Ikram A, Lalani FK. Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infect Drug Resist 2018;11:447-56. doi: 10.2147/IDR.S153116.

9. Nenoff , P Krüger C, Neumeister C, Schwantes U, Koch D. In vitro susceptibility testing of yeasts to nystatin–low minimum inhibitory concentrations suggest no indication of in vitro resistance of Candida albicans, Candida species or non-Candida yeast species to nystatin. Clin and Med Invest 2016;1:71-6. doi: 10.15761/CMI.1000116.

10. Rezaei-Matehkolaei A, Shafiei S, Zarei-Mahmoudabadi A. Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species. Iran J Microbiol 2016;8:410-17.

11. Abastabar M, Mirhendi H, Rezaei‐Matehkolaei A, Shidfar MR, Kordbacheh P, Makimura K. Restriction analysis of β‐tubulin gene for differentiation of the common pathogenic dermatophytes. J Clin Lab Anal 2014;28:91-6. doi 10.1002/jcla.21649.

12. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard–3Th Ed: M27-A3. CLSI, Wayne, PA, USA, 2012.

13. Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th Ed. M27-S4. CLSI, Wayne, PA, USA, 2017

14. Berkow E L, Lockhart SH R, Ostrosky-Zeichner L. Antifungal Susceptibility Testing: Current Approaches. Clin Microbiol Rev 2020; 33: e00069-19. doi: 10.1128/CMR.00069-19.

15. Mohammadi F, Hemmat N, Bajalan Z, Javadi A. Analysis of Biofilm-Related Genes and Antifungal Susceptibility Pattern of Vaginal Candida albicans and Non-Candida albicans Species. Biomed Res Int 2021; 28:2021:5598907 . doi: 10.1155/2021/5598907.

16. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol 2011;3:183- 8.

17. Shokouhi T, Bandalizdeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol 2011; 4: S19-S26.

18. Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, Ghahri M, Shidfar MR, Jalalizand N, et al. Molecular identification and distribution profile of Candida species isolated from Iranian patients. Med Mycol 2013;51:657-63. doi: 10.3109/13693786.2013.770603.

19. Hamzehee S, Kalantar-Neyestanaki D, Afshari SAK, Mousavi SAA. Molecular identification of Candida species, assessment of the antifungal susceptibility and the genetic relationship of Candida albicans isolated from immunocompromised patients in Kerman, Iran. Gene Rep 2019;17:100484 .doi: 10.1016/j.genrep.2019.100484.

20. Mohamadi J, Motaghi M. Anti-fungal resistance in candida isolated from oral and diaper rash candidiasis in neonates. Bioinformation 2014;10:667-70. doi: 10.6026/97320630010667.

21. Yenisehirli G, Bulut N, Yenisehirli A, Bulut Y. In vitro susceptibilities of Candida albicans isolates to antifungal agents in Tokat,Turkey. Jundishapur J Microbiol 2015;8:e28057. doi: 10.5812/jjm.28057.

22. Badiee P, Badali H, Boekhout T, Diba K, Moghadam AG, Nasab AH, et al. Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. BMC Infect Dis 2017;17:727. doi: 10.1186/s12879-017-2825-7.

23. Razzaghi-Abyaneh M, Sadeghi G, Zeinali E, Alirezaee M, Shams-Ghahfarokhi M, Amani A, et al. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. J Mycol Med 2014;24:e43-e50. doi: 10.1016/j.mycmed.2014.01.004.

24. Katiraee F, Teifoori F, Soltani M. Emergence of azole-resistant Candida species in AIDS patients with oropharyngeal Candidiasis in Iran. Curr Med Mycol 2015;1:11-16. doi: 10.18869/acadpub.cmm.1.3.11

25. Jafarian H, Gharaghani M, Seyedian SS, Mahmoudabadi AZ. Genotyping, antifungal susceptibility, enzymatic activity, and phenotypic variation in Candida albicans from esophageal candidiasis. J Clin Lab Anal 2021;35:e23826. doi: 10.1002/jcla.23826.

26. Lotfali E, Cheraghi Z, Farzaneh Y, Dehbashi Z, Dorrian M, Keymaram M, et al. Antifungal susceptibility to azoles drugs in Candida species isolated from patients with onychomycosis. J Cosmet Dermatol Cosmet 2021;12:91-100.

27. Samiei F, Ajudani Far H, Moazeni M. Molecular identification and antifungal susceptibility of Candida albicans isolated from Vulvovaginitis Candidiasis. Int J Mol Clin Microbiol 2014;4:383-8.

28. Amirrajab N, Badali H, Didehdar M, Afsarian MH, Mohammadi R, Lotfi N, et al. In vitro activities of six antifungal drugs against Candida glabrata isolates: an emerging pathogen. Jundishapur J Microbiol 2016;9: e36638. doi: 10.5812/jjm.36638.

29. Shokoohi G, Rasekh-Jahromi A, Solhjoo K, Hasannezhad A, Nouripour-Sisakht S, Ahmadi B, et al. Molecular characterization and antifungal susceptibility of Candida species isolated from vulvovaginitis in Jahrom City, south of Iran. Jundishapur J Microbiol 2020;13:e106825. doi:10.5812/jjm.106825.

30. Kermani F, Sadeghian M, Shokohi T, Hashemi S, Moslemi D, Davodian S, et al. Molecular identification and antifungal susceptibility testing of Candida species isolated from oral lesions in patients with head and neck cancer undergoing radiotherapy. Curr Med Mycol 2021;7:44-50. doi: 10.18502/cmm.7.1.6242. 10.18502/CMM.7.1.6242

31. Mohammadi F, Javaheri MR, Nekoeian S, Dehghan P. Identification of Candida species in the oral cavity of diabetic patients. Curr Med Mycol 2016;2:1.7 .doi: 10.18869/acadpub.cmm.2.2.4.

32. Hashemi SE, Shokohi T, Abastabar M, Aslani N, Ghadamzadeh M, Haghani I. Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae. Curr Med Mycol 2019;5:26-34. doi: 10.18502/cmm.5.4.2062.